Illumina Announces Winners of MiSeq® Grant Program

  Illumina Announces Winners of MiSeq® Grant Program

   Awards Will Accelerate Original Research in Microbial Ecology, Neglected
                          Disease, and Human Health

Business Wire

SAN DIEGO -- November 07, 2012

Illumina, Inc. (NASDAQ:ILMN) today announced the winners of its MiSeq grant
program at the American Society of Human Genetics (ASHG) annual meeting in San
Francisco. Illumina received almost 850 applications from researchers in over
40 countries in fields as diverse as microbiology, cancer, inherited disease,
and evolutionary biology.

The awardees are:

  *Ramunas Stepanauskas, from the Bigelow Laboratory for Ocean Sciences, East
    Boothbay, Maine, for sequencing single cells from unculturable strains of
    bacteria in the dark ocean;
  *Stephen Doyle, from La Trobe University, Melbourne, Australia, for
    investigating drug resistance in the causative agent of African river
    blindness; and
  *Karin Haack, from the Texas Biomedical Research Institute, San Antonio,
    Texas, for targeted resequencing of genes implicated in cardiovascular
    disease.

“We are excited to broaden access to MiSeq and engage with researchers who are
developing novel applications with Illumina technology,” said Gary Schroth,
Distinguished Scientist at Illumina. “The grant applications we received
showed an incredible range of creativity. We look forward to working with the
grant recipients as they make discoveries, innovate, and accelerate the
research being done in their areas of expertise.”

The MiSeq grant program was developed to enable any researcher – from novices
to current Illumina customers anywhere in the world – to gain access to next
generation sequencing (NGS) to further their research, as well as to advance
innovation in applications that can only be enabled by NGS capabilities.

Entries were judged by a team of scientific reviewers from Illumina and
evaluated based upon scientific merit, originality, and applicability to the
unique capabilities of the MiSeq system. Each of the three winners will
receive a MiSeq, sample preparation and sequencing reagent kits, data analysis
software and storage, training, and technical support valued at more than
$150,000 per prize.

For more information, please visit: www.illumina.com/miseqgrant.

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer
of life science tools and integrated systems for the analysis of genetic
variation and function. We provide innovative sequencing and array-based
solutions for genotyping, copy number variation analysis, methylation studies,
gene expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products accelerate
genetic analysis research and its application, paving the way for molecular
medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release may contain forward-looking statements that involve risks and
uncertainties. Important factors that could cause actual results to differ
materially from those in any forward-looking statements are detailed in our
filings with the Securities and Exchange Commission, including our most recent
filings on Forms 10-K and 10-Q, or in information disclosed in public
conference calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date of this
release.

Contact:

Illumina, Inc.
Investors:
Rebecca Chambers, 858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple, 858-882-6822
pr@illumina.com
 
Press spacebar to pause and continue. Press esc to stop.